• LAST PRICE
    38.8500
  • TODAY'S CHANGE (%)
    Trending Up0.1500 (0.3876%)
  • Bid / Lots
    38.0200/ 2
  • Ask / Lots
    40.6600/ 1
  • Open / Previous Close
    38.9400 / 38.7000
  • Day Range
    Low 38.3147
    High 39.4400
  • 52 Week Range
    Low 23.1400
    High 45.2300
  • Volume
    192,820
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 38.7
TimeVolumeMIRM
09:32 ET193638.84
09:39 ET20038.3147
09:43 ET1228538.43
09:45 ET10038.4325
09:48 ET10038.605
09:50 ET10038.45
09:52 ET20038.615
09:54 ET10038.45
09:57 ET10038.46
09:59 ET10038.61
10:01 ET10038.485
10:03 ET10038.555
10:08 ET30038.64
10:10 ET10038.65
10:12 ET10038.675
10:14 ET62638.8
10:15 ET10038.775
10:17 ET10038.7325
10:19 ET20038.78
10:21 ET10038.755
10:32 ET10038.965
10:33 ET20038.89
10:35 ET40038.915
10:37 ET20038.93
10:39 ET230039
10:44 ET10039.01
10:46 ET10039.05
10:48 ET10039.025
10:50 ET10039.08
10:51 ET20039.01
10:57 ET110038.94
11:00 ET73739.155
11:02 ET20039.16
11:06 ET46939.15
11:09 ET30039.07
11:11 ET10039.125
11:15 ET10039.06
11:18 ET10039.125
11:20 ET30039.2
11:22 ET30039.184
11:26 ET10039.1
11:27 ET110039.095
11:29 ET10039.17
11:36 ET48239.22
11:40 ET12339.1601
11:42 ET10039.27
11:49 ET10039.31
11:51 ET10039.29
11:54 ET40039.27
11:58 ET506039.425
12:00 ET238539.21
12:02 ET320039.215
12:03 ET20039.215
12:12 ET40039.145
12:14 ET1325039.16
12:16 ET20039.105
12:20 ET10039.1
12:21 ET20039.06
12:27 ET38939.03
12:30 ET100039.16
12:34 ET10039.16
12:38 ET10039.25
12:39 ET10039.27
12:45 ET10039.15
12:48 ET20039.195
12:54 ET10039.15
12:56 ET70739.22
12:57 ET10039.23
01:01 ET10039.18
01:03 ET36839.27
01:17 ET20039.26
01:19 ET128139.19
01:26 ET143139.325
01:30 ET10039.39
01:33 ET30039.395
01:37 ET90039.36
01:39 ET150039.21
01:42 ET20039.05
01:44 ET529038.9205
01:46 ET10039.06
01:48 ET62439.08
01:50 ET10039.15
01:55 ET79539.07
01:57 ET100039.12
02:04 ET50039.0825
02:08 ET50039.05
02:15 ET50039.1
02:20 ET30039.01
02:26 ET10038.9686
02:27 ET50038.91
02:29 ET20038.93
02:33 ET30038.78
02:44 ET10038.76
02:45 ET10038.83
02:47 ET50038.88
02:54 ET10038.87
02:56 ET10038.89
02:58 ET10038.89
03:02 ET20038.885
03:03 ET157338.81
03:05 ET50038.76
03:07 ET20038.795
03:14 ET30138.795
03:18 ET114938.76
03:21 ET60038.76
03:25 ET42838.76
03:27 ET125038.89
03:30 ET30038.91
03:32 ET30038.87
03:34 ET30038.84
03:38 ET230038.76
03:39 ET50038.86
03:41 ET25038.83
03:43 ET15538.84
03:45 ET60038.815
03:48 ET10038.79
03:52 ET114038.815
03:54 ET43038.89
03:56 ET154438.79
03:57 ET643138.855
03:59 ET3479938.85
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMIRM
Mirum Pharmaceuticals Inc
2.0B
-16.2x
---
United StatesMNKD
MannKind Corp
1.7B
172.8x
---
United StatesVCEL
Vericel Corp
2.2B
2,284.0x
---
United StatesXNCR
Xencor Inc
1.5B
-7.0x
---
United StatesZLAB
Zai Lab Ltd
2.1B
-7.7x
---
United StatesKNSA
Kiniksa Pharmaceuticals Ltd
1.8B
-139.8x
---
As of 2024-09-28

Company Information

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Contact Information

Headquarters
989 EAST HILLSDALE BOULEVARD, SUITE 300FOSTER CITY, CA, United States 94404
Phone
650-667-4085
Fax
302-269-3855

Executives

Independent Non-Executive Chairman of the Board
Michael Grey
President, Chief Operating Officer
Peter Radovich
Chief Executive Officer, Co-Founder, Director
Christopher Peetz
Chief Financial Officer
Eric Bjerkholt
Chief Scientific Officer
Pamela Vig

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.0B
Revenue (TTM)
$264.4M
Shares Outstanding
47.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.14
EPS
$-2.40
Book Value
$5.32
P/E Ratio
-16.2x
Price/Sales (TTM)
7.4
Price/Cash Flow (TTM)
---
Operating Margin
-41.01%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.